scholarly journals Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab

2021 ◽  
Vol 7 ◽  
Author(s):  
Ava Diarra ◽  
Guillaume Gantois ◽  
Mouna Lazrek ◽  
Basile Verdier ◽  
Vincent Elsermans ◽  
...  
Keyword(s):  
Genetically Engineered ◽  
Risk Of Infection ◽  
Viral Pathogens ◽  
Giant Cell Myocarditis ◽  
Source Of Infection ◽  
Devic’S Syndrome ◽  
Coxsackie B Viruses ◽  
Anti Cd20 ◽  
Difficult Cases ◽  
Coxsackie B

Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.

Assessment of the risk of infection associated with Coxsackie B viruses in drinking water

2002 ◽  
Vol 2 (3) ◽  
pp. 1-8 ◽  
Author(s):  
J.C. Vivier ◽  
M.M. Ehlers ◽  
W.O.K. Grabow ◽  
A.H. Havelaar
Keyword(s):  
Drinking Water ◽  
Water Treatment ◽  
Clinical Manifestations ◽  
Upper Respiratory Tract ◽  
Risk Of Infection ◽  
Water Supplies ◽  
Treatment Unit ◽  
Coxsackie B Viruses ◽  
Treated Drinking Water ◽  
Coxsackie B

The risk of infection constituted by enteroviruses detected in drinking water supplies analysed in this study were assessed. Coxsackie B viruses (CBV) were used as a model in these assessments. A high proportion of Coxsackie B virus infections are asymptomatic. However, clinical manifestations may range from mild, undifferentiated febrile illness or upper respiratory tract infection to a severe, systemic and sometimes fatal disease of sensitive populations. Dose-response studies suggested that an exponential model best describes infectivity of CBV. The analysis of 172 samples of treated drinking water supplies described in this study revealed the presence of CBVs in 11% (water treatment unit A) and 16% (water treatment unit B) of the samples. This incidence of CBV was used as a basis for risk assessment. The results indicated that the drinking water supplies concerned constitute a risk of CBV infection of 3.91 × 10-3 (unit A) and 7.4 × 10-3 (unit B) per year. The estimated risk of infection are about an order of magnitude higher than the yearly acceptable risk of one infection per 10,000 consumers proposed for drinking water supplies.

Intratypic antigenic heterogeneity of Coxsackie B viruses

1963 ◽  
Vol 12 (1) ◽  
pp. 29-41 ◽  
Author(s):  
Reinhard Wigand ◽  
Albert B. Sabin
Keyword(s):  
Coxsackie B Viruses ◽  
Antigenic Heterogeneity ◽  
Coxsackie B

Coxsackie B viruses and autoimmune diabetes

1982 ◽  
Vol 101 (4) ◽  
pp. 647-648 ◽  
Author(s):  
C.S. Bartsocas ◽  
C.J. Papadatos ◽  
M. Lab ◽  
N. Spyrou ◽  
B. Krikelis ◽  
...  
Keyword(s):  
Autoimmune Diabetes ◽  
Coxsackie B Viruses ◽  
Coxsackie B

scholarly journals RNA Recombination Plays a Major Role in Genomic Change during Circulation of Coxsackie B Viruses

2004 ◽  
Vol 78 (6) ◽  
pp. 2948-2955 ◽  
Author(s):  
M. Steven Oberste ◽  
Silvia Peñaranda ◽  
Mark A. Pallansch
Keyword(s):  
Phylogenetic Trees ◽  
Clinical Isolates ◽  
Human Enterovirus ◽  
Rna Recombination ◽  
Genomic Change ◽  
Genome Region ◽  
Nontranslated Region ◽  
Frequent Event ◽  
Coxsackie B Viruses ◽  
Coxsackie B

ABSTRACT RNA recombination has been shown to occur during circulation of enteroviruses, but most studies have focused on poliovirus. To examine the role of recombination in the evolution of the coxsackie B viruses (CVB), we determined the partial sequences of four genomic intervals for multiple clinical isolates of each of the six CVB serotypes isolated from 1970 to 1996. The regions sequenced were the 5′-nontranslated region (5′-NTR) (350 nucleotides [nt]), capsid (VP4-VP2, 416 nt, and VP1, ∼320 nt), and polymerase (3D, 491 nt). Phylogenetic trees were constructed for each genome region, using the clinical isolate sequences and those of the prototype strains of all 65 enterovirus serotypes. The partial VP1 sequences of each CVB serotype were monophyletic with respect to serotype, as were the VP4-VP2 sequences, in agreement with previously published studies. In some cases, however, incongruent tree topologies suggested that intraserotypic recombination had occurred between the sequenced portions of VP2 and VP1. Outside the capsid region, however, isolates of the same serotype were not monophyletic, indicating that recombination had occurred between the 5′-NTR and capsid, the capsid and 3D, or both. Almost all clinical isolates were recombinant relative to the prototype strain of the same serotype. All of the recombination partners appear to be members of human enterovirus species B. These results suggest that recombination is a frequent event during enterovirus evolution but that there are genetic restrictions that may influence recombinational compatibility.

Association between group G chromosomes, especially chromosome G21, and susceptibility of human cells to coxsackie B viruses

1978 ◽  
Vol 86 (5) ◽  
pp. 1493-1496
Author(s):  
Ya. E. Khesin ◽  
A. M. Amchenkova ◽  
N. E. Gulevich ◽  
A. N. Narovlyanskii
Keyword(s):  
Human Cells ◽  
Coxsackie B Viruses ◽  
Coxsackie B

Echoviruses and Coxsackie B Viruses That Use Human Decay‐Accelerating Factor (DAF) as a Receptor Do Not Bind the Rodent Analogues of DAF

2000 ◽  
Vol 181 (1) ◽  
pp. 340-343 ◽  
Author(s):  
O. Brad Spiller ◽  
Ian G. Goodfellow ◽  
David J. Evans ◽  
Jeffrey W. Almond ◽  
B. Paul Morgan
Keyword(s):  
Decay Accelerating Factor ◽  
Coxsackie B Viruses ◽  
Coxsackie B

scholarly journals Chronic Refractory Idiopathic Thrombocytopenic Purpura (ITP) and Anti-CD20 Monoclonal Antibody: A Case Report

2006 ◽  
Vol 12 (4) ◽  
pp. 489-492 ◽  
Author(s):  
S. Z. Latifzadeh ◽  
V. Entezari
Keyword(s):  
Monoclonal Antibody ◽  
Platelet Count ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Specific Antigen ◽  
Genetically Engineered ◽  
Low Grade ◽  
Treatment Schedule ◽  
Thrombocytopenic Purpura ◽  
Anti Cd20 ◽  
Refractory Itp

Idiopathic thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by accelerated and premature destruction of platelets by reticuloendothelial system. CD20, a trans-membrane B-cell-specific antigen, is a potential target for treatment of certain malignant and nonmalignant plasma cell disorders including refractory ITP. Rituximab is a genetically engineered human anti-CD20 monoclonal antibody, which is approved for the treatment of low-grade non-Hodgkin’s lymphoma. Recent clinical reports suggest that rituximab may be useful in treating certain patients with chronic refractory ITP. A 59-year-old woman with refractory ITP was placed on rituximab (four weekly doses of 375 mg/m2) and her condition and platelet count were observed for 18 months. There was a gradual increase in platelet count and she was symptom free in this period and no side effects of the drug were reported. Anti-CD20 antibodies are likely to be used in the treatment of refractory ITP cases, but further studies about treatment schedule and criteria for patient selection should be done.

Coxsackie B viruses use multiple receptors to infect human cardiac cells

2004 ◽  
Vol 74 (2) ◽  
pp. 291-299 ◽  
Author(s):  
George Orthopoulos ◽  
Kathy Triantafilou ◽  
Martha Triantafilou
Keyword(s):  
Cardiac Cells ◽  
Multiple Receptors ◽  
Coxsackie B Viruses ◽  
Coxsackie B
Sign in / Sign up

Export Citation Format

Share Document